✦ LIBER ✦

Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

✍ Scribed by Arévalo, Estefanía; Castañón, Eduardo; López, Inés; Salgado, Josefa; Collado, Víctor; Santisteban, Marta; Rodríguez-Ruiz, María; Martín, Patricia; Zubiri, Leire; Patiño-García, Ana; Rolfo, Christian; Gil-Bazo, Ignacio

Book ID: 125401223
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 427 KB
Volume: 12
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-12-98

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of pemetrexed as a third- o

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

✍ Chang, Myung Hee; Ahn, Jin Seok; Lee, Jeeyun; Kim, Kyoung Ha; Park, Yeon Hee; Ha 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 466 KB

Histology as a Potential Clinical Predic

Histology as a Potential Clinical Predictor of Outcome in Advanced Non-Small-Cell Lung Cancer Treated with Vinorelbine and Mitomycin Combination Chemotherapy

✍ Thomas Wibmer, Thierry Berghmans, Cornelia Kropf-Sanchen, Jean-Jacques Lafitte… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 233 KB

OP62 Polymorphisms in AKT1 and EGFR as p

OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib

✍ E. Giovannetti; P. Zucali; C. Tibaldi; E. Smit; A. Falcone; A. Santoro; L. Leon; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 41 KB